Fundraising Fox
Biomodal
Cambridge, GB · 6 known investors
Find your way into Biomodal
Sign up to see every warm intro you have to Biomodal
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Biomodal team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Biomodal develops genomic and epigenomic sequencing technologies for life scientists and clinical researchers, enabling simultaneous analysis of genetic data and modified cytosine bases from a single DNA sample. The company's tools integrate pre- and post-sequencing workflows to capture both canonical and modified bases in the genome.
Founders & leadership
Board
Investors · 6
How we know: GV (Google Ventures)'s portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: New Science Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Sequoia Capital's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Companies House · registry record
View on Companies House ↗- Registered name
- BIOMODAL LIMITED
- Company number
- 08005377
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 26 Mar 2012
- Registered office
- B400, The Trinity Building Chesterford Business Park, Little Chesterford, Saffron Walden, CB10 1XL
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Previous names
- CAMBRIDGE EPIGENETIX LIMITED (2012–2023)NEWINCCO 1171 LIMITED (2012–2012)
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 26 Mar 2026 · next due 9 Apr 2027
Current officers · 7
- Fiona Stewart — secretary, appointed 30 Jul 2020
- Shankar Balasubramanian — director, appointed 20 Apr 2012
- Peter John Fromen — director, appointed 18 Jul 2022
- Thomas William Hulme — director, appointed 18 Dec 2015
- Gail Marcus — director, appointed 20 Sept 2018
- Omead Ostadan — director, appointed 20 Jul 2022
- Peter James Wrighton-Smith — director, appointed 25 Oct 2023
Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Biomodal do?
- Biomodal develops genomic and epigenomic sequencing technologies for life scientists and clinical researchers, enabling simultaneous analysis of genetic data and modified cytosine bases from a single DNA sample. The company's tools integrate pre- and post-sequencing workflows to capture both canonical and modified bases in the genome.
- Who are Biomodal's investors?
- Biomodal's investors include GV (Google Ventures), JIMCO, New Science Ventures, Sequoia Capital, Ahren Innovation Capital, University of Cambridge Enterprise.
- Where is Biomodal headquartered?
- Biomodal is headquartered in Cambridge, GB.